Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A trial investigating how effective endocrine treatment is, prior to surgery in post-menopausal women with breast cancer, has randomised its first patient of the year.

The EndoNET trial team, investigators and research nurses.

Over 50,000 women develop breast cancer each year in the UK. The current standard of care is surgery within a month of diagnosis, followed by radiotherapy for some, and anti-hormone therapy (known as endocrine treatment) for 5-10 years. Over 40% of patients will be treated by surgical removal of the breast, while others may require surgery where only a limited amount of tissue is removed (breast conservation surgery).

Endocrine treatment after surgery is very effective in the long-term treatment of breast cancer; but it is unknown whether starting this same endocrine treatment before surgery, known as “neo-adjuvant endocrine therapy”, is also beneficial. The EndoNET trial, led by Professor Michael Douek and Professor Ramsey Cutress, is run by the Surgical Intervention Trials Unit (Nuffield Department of Surgical Sciences) and seeks to evaluate whether six months of endocrine treatment before surgery can shrink the tumour prior to operating, which could reduce the extent of breast surgery required.

The trial’s first patient of 2023 was successfully randomised on 3rd January at St Albans City Hospital. EndoNET aims to recruit a total of 1,440 women from 30+ hospitals across the UK, and is being led by the University of Oxford in collaboration with investigators at the University of Southampton and the University of Bristol.

Commenting on EndoNET’s early recruitment success, Lead Investigator Professor Cutress of the University of Southampton said:

“We are absolutely thrilled that the trial has opened and patients from a number of sites have already taken the opportunity to participate. EndoNET is a national, multicentre, randomised controlled clinical trial funded by the National Institute for Health Research. It is designed to understand if a period of treatment with hormone therapy prior to surgery reduces the requirement for mastectomy and improves quality of life. This is important to patients, and was identified as a research priority by NICE, so it’s fantastic that this research is now up and running.”

Similar stories

New Cochrane review on antihistamines for motion sickness

A new systematic review from Cochrane ENT at the Nuffield Department of Surgical Sciences says antihistamines are likely to reduce the risk of developing motion sickness (travel sickness) in susceptible adults under naturally occurring conditions of movement, but they may be more likely to cause drowsiness than placebo.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Dimitrios Doultsinos wins Young Investigator Award from the Prostate Cancer Foundation

Dr Dimitrios Doultsinos, a John Black Research Fellow in Prostate Oncology at Oxford University's Nuffield Department of Surgical Sciences (NDS), was one of this year’s recipients of the highly coveted Prostate Cancer Foundation (PCF) Young Investigator Award.

Blog posts

Marathon challenge for Prostate Cancer UK

Runners of all abilities started 2023 by challenging themselves to run 26.2 miles across January to fundraise for Prostate Cancer UK as part of the charity’s Run the Month: Marathon Edition.

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.